Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan:63:101138.
doi: 10.1016/j.blre.2023.101138. Epub 2023 Oct 13.

Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East

Amal El-Beshlawy  1 , Hany Dewedar  2 , Salwa Hindawi  3 , Salam Alkindi  4 , Azza A Tantawy  5 , Mohamed A Yassin  6 , Ali T Taher  7
Affiliations
Free article
Review

Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East

Amal El-Beshlawy et al. Blood Rev. 2024 Jan.
Free article

Abstract

β-Thalassemia is one of the most common monogenetic diseases worldwide, with a particularly high prevalence in the Middle East region. As such, we have developed long-standing experience with disease management and devising solutions to address challenges attributed to resource limitations. The region has also participated in the majority of clinical trials and development programs of iron chelators and more novel ineffective erythropoiesis-targeted therapy. In this review, we provide a practical overview of management for patients with transfusion-dependent β-thalassemia, primarily driven by such experiences, with the aim of transferring knowledge to colleagues in other regions facing similar challenges.

Keywords: Complications; Management; Thalassemia; Transfusion; iron chelation.

PubMed Disclaimer

Conflict of interest statement

Disclosures A.E-B. reports consultancy fees from Bristol Myers Squibb. H.D. reports consultancy fees from Bristol Myers Squibb, Novartis, and Chiesi; and research funding from Agios Pharmaceuticals. S.H. reports consultancy fees from Bristol Myers Squibb. S.A. reports consultancy fees from Bristol Myers Squibb and Novartis. A.A.T. reports consultancy fees from Bristol Myers Squibb. M.A.Y. reports consultancy fees from Bristol Myers Squibb. A.T.T. reports consultancy fees from Novartis, Celgene Corp (Bristol Myers Squibb), Agios Pharmaceuticals, Vifor Pharma, and Pharmacosmos; and research funding from Novartis, Celgene Corp (Bristol Myers Squibb), Agios Pharmaceuticals, Vifor Pharma, and Pharmacosmos.

Publication types

Substances